Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 27.10.2023GlaxoSmithKline (Ireland) Limited (GAG-IE-2)46802INTEGRILIN 0,75 mg/ml infúzny roztok (sol inf 1x100 ml/75 mg (liek.inj.skl.))27.10.2023Z
 27.10.2023MEDOCHEMIE Ltd. (MOE)5231BAXETINE 250 mg (tbl flm 10x250 mg (blis.Al/Al))17.10.2023R
 27.10.2023MEDOCHEMIE Ltd. (MOE)5243BAXETINE 500 mg (tbl flm 10x500 mg (blis.Al/Al))28.9.2023R
 27.10.2023MEDOCHEMIE Ltd. (MOE)33522MEDOCLAV 625 mg (tbl flm 21x625 mg (blis.Al/PVC))26.10.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)3671CMEDOCLAV 400 mg/5 ml + 57 mg/5 ml prášok na perorálnu suspenziu (plu por 1x70 ml (fľ.skl.hnedá+dáv.striek.))6.9.2023R
 27.10.2023MEDOCHEMIE Ltd. (MOE)39164MEDOCLAV 1 g (tbl flm 14x1 g (blis.Al/PVC))25.10.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)5231BAXETINE 250 mg (tbl flm 10x250 mg (blis.Al/Al))10.10.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)5243BAXETINE 500 mg (tbl flm 10x500 mg (blis.Al/Al))13.9.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)33520MEDOCLAV 375 mg (tbl flm 21x375 mg (blis.Al/PVC))23.8.2023R
 27.10.2023MEDOCHEMIE Ltd. (MOE)33520MEDOCLAV 375 mg (tbl flm 21x375 mg (blis.Al/PVC))17.8.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)33522MEDOCLAV 625 mg (tbl flm 21x625 mg (blis.Al/PVC))18.8.2023R
 27.10.2023MEDOCHEMIE Ltd. (MOE)3671CMEDOCLAV 400 mg/5 ml + 57 mg/5 ml prášok na perorálnu suspenziu (plu por 1x70 ml (fľ.skl.hnedá+dáv.striek.))17.8.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)39164MEDOCLAV 1 g (tbl flm 14x1 g (blis.Al/PVC))9.8.2023R
 27.10.2023MEDOCHEMIE Ltd. (MOE)9445BZEPILEN 1 g (plo ijf 10x1 g (liek.inj.skl.))1.8.2023O
 27.10.2023MEDOCHEMIE Ltd. (MOE)5231BAXETINE 250 mg (tbl flm 10x250 mg (blis.Al/Al))25.7.2023R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)